Aclaris Therapeutics
ACRS
ACRS
115 hedge funds and large institutions have $851M invested in Aclaris Therapeutics in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 27 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
1.73% less ownership
Funds ownership: 96.76% → 95.03% (-1.7%)
16% less capital invested
Capital invested by funds: $1.02B → $851M (-$166M)
Holders
115
Holding in Top 10
9
Calls
$541K
Puts
$286K
Top Buyers
| 1 | +$36M | |
| 2 | +$9.53M | |
| 3 | +$8.68M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$5.82M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.69M |
Top Sellers
| 1 | -$11.6M | |
| 2 | -$7.58M | |
| 3 | -$5.07M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.08M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.61M |